Trade Analytics

Lupin Pharmaceuticals

Go Back

Lupin Pharmaceuticals

  • Amongst the top 10 generic companies in the world
  • Fifth largest pharma company in India in 2017 as per Moving Annual Turnover (MAT)
  • 18 manufacturing sites
  • Products sold in more than 100 countries

Lupin Ltd is a leading pharmaceutical company from India and is amongst the top 10 generic companies in the world. It started its business in 1968 and over the years has become one of the largest pharmaceutical companies in India and the world. Its businesses include formulations, Active Pharmaceutical Ingredients (API), drug delivery systems and biotechnology.  Its largest market is the North American region which contributed 38 per cent of its revenues in FY18, followed by India with 26 per cent and Asia-Pacific (APAC) with 17 per cent. Its net sales reached Rs 15,560 crore (US$ 2.41 billion) in FY18. In FY19, its total sales reached Rs 16369.4 crore (US$ 2.34 billion).

Company Website:

2017 Entered over the counter (OTC) market with launch of Softovac in India
2016 Acquired US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc.
2010 Became fifth largest generic player in the US
2004 Commenced US Brands Business with the launch of Suprax
2002 More than 100 patent filings
1993 Lupin Laboratories Ltd. and Lupin Chemicals Ltd. raise money through IPOs
1989 Joint venture in Thailand and Lupin Chemicals (Thailand) Ltd was formed
1980 Commissioned first Formulations plant and an R&D center at Aurangabad, Maharashtra
1968 Commenced business


Updated: May, 2019

The exports are expected to reach US$ 20 billion by 2020.